NEW YORK – HalioDx on Tuesday announced an extended strategic collaboration with Kite Pharma aimed at developing and validating immune-based biomarkers for the drug firm's investigational therapies.
The deal covers multiple blood cancer and solid tumor indications and will leverage Marseille, France-based HalioDx's Immunoscore immune-based tests. Immunogram, the company's multiparameter approach for the analysis of the immune microenvironment of tumors, as well as HalioDx's Cancer Immune Atlas will also be used.